Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06235801 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
A Phase 1 study of Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06235801: Recruiting Phase 1 study of Myeloid Leukemia, sponsored by M.D. Anderson Cancer Center.
NCT06235801 is a Phase 1 study of Myeloid Leukemia that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 77-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06235801, a Phase 1 study of Myeloid Leukemia, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Momelotinib
- DRUG Gilteritinib
Study Locations (1)
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-05-22 |
| Est. Completion | 2029-10-01 |
| Phase | Phase 1 |
What NCT06235801 shows while recruiting
NCT06235801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 77-participant average among 6 other Myeloid Leukemia trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Momelotinib is the first listed.
NCT06235801 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06235801 about?
NCT06235801 is a clinical study titled "A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia". To learn the recommended dose of momelotinib that can be given in combination with gilteritinib to participants with AML.
What is the current status of trial NCT06235801?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-05-22. Estimated completion is 2029-10-01.
What conditions does trial NCT06235801 study?
This clinical trial studies the following conditions: Myeloid Leukemia.
What interventions are being tested in trial NCT06235801?
The interventions under investigation include: Momelotinib (DRUG), Gilteritinib (DRUG).
Who is sponsoring clinical trial NCT06235801?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06235801 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
RECRUITING · Phase 1
-
Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia
COMPLETED · Phase 1
-
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
RECRUITING · Phase 2
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI